dimethyl-(3-{4-[3-(2-trifluoromethyl-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-propyl)-amine | 3829-61-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: dimethyl-(3-{4-[3-(2-trifluoromethyl-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-propyl)-amine
• 英文别名: N,N-dimethyl-3-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]propan-1-amine
• CAS: 3829-61-6
• 化学式: C₂₅H₃₃F₃N₄S
• 分子量: 478.625
• InChiKey: IBEUEFNPWNPPGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  38.3
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1-甲酰基-4-(3-氯丙基)哌嗪 反应 4.0h， 生成 dimethyl-(3-{4-[3-(2-trifluoromethyl-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-propyl)-amine
  参考文献：
  名称：

  ANDERSON, Arzneimittel-Forschung/Drug Research, 1962, vol. 12, p. 937 - 942

  摘要：

  DOI：

文献信息

• NUPR1 INHIBITION FOR TREATING CANCER
  申请人：INSTITUT NATIONAL DE SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：US20210137938A1

  公开（公告）日：2021-05-13

  The present invention relates to the treatment of a tumor selected from the group consisting of pancreatic cancer, liver cancer, melanoma, colon cancer, glioblastoma, osteosarcoma, prostate cancer and breast cancer, more particularly pancreatic cancer. The inventors found a novel family compounds of formula (I) able to treat a variety of cancers by inhibiting NUPR1, a stress-inducible 82-amino-acid-long, intrinsically disordered member of the AT-hook family of chromatin proteins. Thus, the present invention relates to a compound of formula (I) for its use in the treatment of a tumor selected from the group consisting of pancreatic cancer, liver cancer, melanoma, colon cancer, glioblastoma, osteosarcoma, prostate cancer and breast cancer. In particular, the inventors tested compounds of formula (I) on four well characterized primary pancreatic cancer-derived cells 02.063 and LIPC (Basal subtype), Foic8b (derived from a liver metastasis) and HN14 (Classical subtype), as well as on other cellular lines derived from different tumors, i.e. U87 (glioblastoma), A375 and B16 (melanoma), U20S and SaOS (osteosarcoma), HT29, SK-CO-1 and LS174T (colon cancer), HepG2 (hepatocarcinoma), PC3 (prostate) and MDA-MB-231 (breast cancer). The compounds per se are also claimed.
• ANDERSON, Arzneimittel-Forschung/Drug Research, 1962, vol. 12, p. 937 - 942
  作者：ANDERSON

  DOI：——

  日期：——